Breast cancer claims approximately 670,000 lives annually. According to data from the World Health Organization (WHO), breast cancer was the most prevalent cancer in women in 157 out of 185 countries in 2022. Each year, over 2 million women are diagnosed with breast cancer, underscoring the need for early detection and the development of targeted treatments. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for the early-stage treatment of breast cancer. This drug has been authorized for use in conjunction with hormone therapy for early-stage breast cancer patients, particularly those worried about cancer recurrence. Kisqali works as a selective cyclin-dependent kinase inhibitor, hindering the proteins CDK4/6 that promote rapid growth and division of cancer cells. Administered orally as a pill, Kisqali is typically prescribed for three weeks followed by a one-week break, to be continued for three years, and can be taken with or without food. A daily dose of 400 mg is advised.Kisqali ed.: Adverse Effects

The typical side effects of Kisqali medication include reduced white blood cell count, known as neutropenia. Neutropenia involves decreased levels of neutrophils in the blood, which are crucial for combating infections in the body. Additionally, Kisqali may also cause liver-related problems and interstitial lung disease/pneumonitis.

Breast Cancer: Warning Signs That Should Not Be Overlooked